Insulin resistance is an independent risk factor for early neurological deterioration in non-diabetic patients with acute ischemic stroke
- 18 Downloads
The role of insulin resistance (IR) in stroke prognosis remains largely unknown. This study aimed to investigate the relationship between IR and the risk of early neurological deterioration (END) in non-diabetic patients with acute ischemic stroke.
This is a retrospective analysis of non-diabetic patients with acute ischemic stroke enrolled in the prospective multicenter ACROSS-China study. The homeostasis model assessment 2 (HOMA2-IR) was evaluated and the patients were divided into HOMA2-IR quartiles (Q1 0–1.24, Q2 1.25–1.95, Q3 1.96–2.96, Q4 ≥ 2.97). END was defined as an increment in total National Institutes of Health Stroke Scale (NIHSS) of ≥ 2 points or ≥ 4 points on day 14 ± 3 after stroke onset. Logistic regression was performed to explore the relationship between HOMA2-IR and END.
Finally, 556 patients were included (63.7 ± 12.9 years, 64.6% male); thirty-three patients developed END. The median HOMA2-IR of all patients was 1.95 (inter-quartile = 1.24–2.96). There were 148, 135, 130, and 143 patients in Q1, Q2, Q3, and Q4, respectively. Compared with Q1, END (NIHSS ≥ 2) risk was increased in Q4: adjusted odds ratio (OR) = 6.051, 95% CI = 1.638–22.354, P = 0.0069. In additon, END (NIHSS ≥ 2) risk was increased in Q4 compared with the Q1–Q3 combined group: adjusted OR = 2.853, 95% CI = 1.308–6.224, P = 0.0084. END (NIHSS ≥ 4) risk was also increased in Q4: adjusted OR = 7.507, 95% CI = 2.357–23.906, P = 0.0006) compared with the Q1–Q3 combined group.
This study strongly suggests that IR is probably an independent risk factor for END in non-diabetic patients with acute ischemic stroke.
KeywordsStroke Insulin resistance Early neurological deterioration
Availability of data and materials
The data sets during and/or analyzed during the current study are available from the corresponding author on reasonable request.
This study was supported by the National Natural Science Foundation of China (81601015) and Beijing Talents Fund (2015000021469G220).
Compliance with ethical standards
The authors declare that they have no competing interests.
- 7.Bhatia K, Mohanty S, Tripathi BK, Gupta B, Mittal MK (2015) Predictors of early neurological deterioration in patients with acute ischaemic stroke with special reference to blood urea nitrogen (BUN)/creatinine ratio & urine specific gravity. Indian J Med Res 141(3):299–307PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Jia Q, Zheng H, Zhao X, Wang C, Liu G, Wang Y, Liu L, Li H, Zhong L, Wang Y, Investigators for the Survey on Abnormal Glucose Regulation in Patients With Acute Stroke Across China (ACROSS-China) (2012) Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke 43(3):650–657PubMedCrossRefGoogle Scholar
- 12.Jia Q, Liu G, Zheng H, Zhao X, Wang C, Wang Y, Liu L, Wang Y, Investigators for the Survey on Abnormal Glucose Regulation in Patients With Acute Stroke Across China (2014) Impaired glucose regulation predicted 1-year mortality of Chinese patients with ischemic stroke: data from abnormal glucose regulation in patients with acute stroke across China. Stroke 45(5):1498–1500PubMedCrossRefGoogle Scholar
- 13.Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke, 1989. 20(10): p. 1407–31Google Scholar
- 15.American Diabetes A (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1):S43–S48Google Scholar
- 18.Zhang X et al (2016) Metabolic syndrome augments the risk of early neurological deterioration in acute ischemic stroke patients independent of inflammatory mediators: a hospital-based prospective study. Oxidative Med Cell Longev 2016:8346301Google Scholar
- 20.Calleja, A.I., et al., Blood biomarkers of insulin resistance in acute stroke patients treated with intravenous thrombolysis: temporal profile and prognostic value.J Diab Res Clin Metab, 2013Google Scholar
- 21.Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45(7):2160–2236PubMedCrossRefGoogle Scholar
- 24.Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, IRIS Trial Investigators (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321–1331PubMedPubMedCentralCrossRefGoogle Scholar
- 31.Calleja AI, García-Bermejo P, Cortijo E, Bustamante R, Rojo Martínez E, González Sarmiento E, Fernández-Herranz R, Arenillas JF (2011) Insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic stroke. Diabetes Care 34(11):2413–2417PubMedPubMedCentralCrossRefGoogle Scholar